Levetiracetam as a Potent and Safe Antiepileptic Drug | ||||
Minia Journal of Medical Research | ||||
Volume 31, Issue 3, July 2020, Page 112-123 PDF (309.8 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/mjmr.2022.219927 | ||||
View on SCiNiTO | ||||
Authors | ||||
Ramy M. El Sabaa1; Emad Hamdi2; Nermin Aly Hamdy3; Hatem A. Sarhan2 | ||||
1Department of Clinical Pharmacy, Faculty of Pharmacy, Deraya University, Minia, Egypt. | ||||
2Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt. | ||||
3Department of Neurology, Faculty of Medicine, Minia University, Minia, Egypt. | ||||
Abstract | ||||
A group of new antiepileptic drugs (AEDs) has been clinically established and used. Most of these drugs have new mechanisms of actions that differ from older drugs. Levetiracetam (LEV), a second generation AEDs, is a pyrrolidine derivate compound. The mechanism of action of LEV is different from older AEDs since, it reduces the epileptic seizures through binding to the synaptic vesicle protein 2A (SV2A) receptor. Some studies have reported that LEV, as monotherapy for patients with focal and generalized seizures and safer than AEDs. Other studies concluded that LEV can be used as add-on therapy (Any therapy that is given in addition to the primary or initial therapy to maximize its effectiveness) for patients with focal, myoclonic, and generalized tonic clonic seizures (GTCS). Its pharmacokinetic profile is favorable. It has less drug interaction with other AEDs. This article summarizes the clinical data of LEV in the management of different kinds of epilepsy. | ||||
Keywords | ||||
Levetiracetam; Epilepsy; Efficacy; Safety; Monotherapy; Add-on therapy | ||||
Supplementary Files
|
||||
Statistics Article View: 138 PDF Download: 74 |
||||